RxDoctor Payments Data

Ronald Lahasky, MD

Internal Medicine · Abbeville, LANPI 1487768214

Payments from drug & device makers

$10,475in general payments, 2019–2025

Across 670 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$756
  • Amgen$726
  • Novo Nordisk$640
  • GSK$619
  • Astellas Pharma US Inc$568
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$10,451100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,475 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$380,702
Medicare patients
896
Services billed
5,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban824$279,198
MounjaroTirzepatide166$189,096
TrulicityDulaglutide142$140,292
XareltoRivaroxaban387$120,963
LinzessLinaclotide246$101,030
IngrezzaValbenazine Tosylate22$82,226
Teriflunomide12$74,748
MyrbetriqMirabegron231$65,744
JardianceEmpagliflozin177$64,350
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$61,229
JanuviaSitagliptin Phosphate144$58,070
OzempicSemaglutide56$53,043
Breo ElliptaFluticasone/Vilanterol113$48,450
RexultiBrexpiprazole84$47,732
TrintellixVortioxetine Hydrobromide161$40,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$555$329,389308 claims
PfizerEliquis$550$279,198824 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$619$134,919246 claims
Johnson & JohnsonXarelto$489$120,963387 claims
AbbVieLinzess$756$101,030246 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$271$90,170254 claims
Neurocrine Biosciences, Inc.Ingrezza$23$82,22622 claims
Novo NordiskOzempic, Tresiba$640$77,121123 claims
MerckJanuvia, Janumet$542$67,955175 claims
Astellas Pharma US IncMyrbetriq$568$65,744231 claims
Otsuka America Pharmaceutical, Inc.Rexulti$269$47,73284 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,042$42,98789 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Abbeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →